EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

February 9, 2018: By Jon Swedien

EyeGate Pharmaceuticals’ EGP-437 outperformed the vehicle in its Phase IIb study, but the product candidate for post-cataract pain and inflammation failed to meet the study’s co-primary endpoints.

The vehicle group’s response was better than anticipated, EyeGate said.

The double-masked, randomized, vehicle-controlled Phase IIb study enrolled 106 subjects at seven US clinical sites and evaluated the safety and efficacy of transscleral iontophoretically delivered EGP-437, dexamethasone, through the company’s EyeGate II Delivery System.

Patients in the study had undergone cataract surgery and been implanted with a monofocal posterior chamber IOL. They received treatment beginning immediately after surgery.

The study’s primary endpoints were:

–Proportion of subjects with an anterior chamber cell count of zero at day seven;

–Proportion of subjects with a pain score of zero at day one.

EGP-437 demonstrated a higher rate of success compared with vehicle at all time points, but the difference between its scores and the placebo’s scores did not demonstrate statistical significance, EyeGate said.

EyeGate will continue evaluating EGP-437 for post-ocular surgery pain and inflammation, said Barbara Wirostko, MD, the company’s chief medical officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility